{
    "info": {
        "nct_id": "NCT06188702",
        "official_title": "A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP",
        "inclusion_criteria": "* Estimated life expectancy ≥3 months.\n* ECOG PS 0-1\n* Participants able to comply with highly effective method of birth control requirements.\n* Participants with histologically confirmed advanced or metastatic solid tumor's (excluding central nervous system tumors) that have progressed despite at least one prior treatment regimen given for advanced/metastatic disease, and for whom additional effective standard therapy is not available.\n* Participants with pre-existing documented MTAP homozygous deletion in their tumor tissue, determined using a next generation sequencing in vitro diagnostic test prior to screening.\n* Participants willing to undergo paired fresh biopsy (pre-treatment and post-treatment) procedure. Exceptions may be made for feasibility and safety concerns.\n* Adequate organ functions.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Inability to take an orally administered drug, or medical disorder or prior surgical resection that may affect the absorption of the study drug.\n* Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's Medical monitor and investigator agree and document that it should not be exclusionary.\n* Known prior severe hypersensitivity to any component of the study drug formulation.\n* Major surgery within 4 weeks prior to the first IMP administration or participants who have not recovered from side effects of the surgery.\n* Have a known history of Gilbert's syndrome.\n* Participants with a known clinically significant cardiovascular disease or condition.\n* Participants with thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to first IMP administration.\n* Active brain metastases.\n* Current active liver or biliary disease.\n* Participants who have received systemic anticancer treatment or radiotherapy less than 2 weeks before the first dose of S095035. Participants who have not recovered from toxicity of previous anticancer therapy.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Participants willing to undergo paired fresh biopsy (pre-treatment and post-treatment) procedure. Exceptions may be made for feasibility and safety concerns.",
            "criterions": [
                {
                    "exact_snippets": "Participants willing to undergo paired fresh biopsy (pre-treatment and post-treatment) procedure.",
                    "criterion": "paired fresh biopsy procedure",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "pre-treatment",
                                "post-treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants able to comply with highly effective method of birth control requirements.",
            "criterions": [
                {
                    "exact_snippets": "Participants able to comply with highly effective method of birth control requirements",
                    "criterion": "compliance with highly effective method of birth control",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated life expectancy ≥3 months.",
            "criterions": [
                {
                    "exact_snippets": "Estimated life expectancy ≥3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ functions.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ functions",
                    "criterion": "organ functions",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG PS 0-1",
            "criterions": [
                {
                    "exact_snippets": "ECOG PS 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with pre-existing documented MTAP homozygous deletion in their tumor tissue, determined using a next generation sequencing in vitro diagnostic test prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "pre-existing documented MTAP homozygous deletion in their tumor tissue",
                    "criterion": "MTAP homozygous deletion in tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "determined using a next generation sequencing in vitro diagnostic test",
                    "criterion": "method of MTAP deletion determination",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic method",
                            "expected_value": "next generation sequencing in vitro diagnostic test"
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to screening",
                    "criterion": "timing of MTAP deletion determination",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with histologically confirmed advanced or metastatic solid tumor's (excluding central nervous system tumors) that have progressed despite at least one prior treatment regimen given for advanced/metastatic disease, and for whom additional effective standard therapy is not available.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed advanced or metastatic solid tumor's (excluding central nervous system tumors)",
                    "criterion": "solid tumor diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histological"
                        },
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "central nervous system tumors"
                        }
                    ]
                },
                {
                    "exact_snippets": "have progressed despite at least one prior treatment regimen given for advanced/metastatic disease",
                    "criterion": "disease progression after prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of prior regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        },
                        {
                            "requirement_type": "treatment setting",
                            "expected_value": "advanced/metastatic disease"
                        }
                    ]
                },
                {
                    "exact_snippets": "for whom additional effective standard therapy is not available",
                    "criterion": "availability of effective standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Have a known history of Gilbert's syndrome.",
            "criterions": [
                {
                    "exact_snippets": "known history of Gilbert's syndrome",
                    "criterion": "Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active brain metastases.",
            "criterions": [
                {
                    "exact_snippets": "Active brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current active liver or biliary disease.",
            "criterions": [
                {
                    "exact_snippets": "Current active liver or biliary disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "current active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Current active liver or biliary disease",
                    "criterion": "biliary disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "current active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's Medical monitor and investigator agree and document that it should not be exclusionary.",
            "criterions": [
                {
                    "exact_snippets": "Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's Medical monitor and investigator agree and document that it should not be exclusionary.",
                    "criterion": "active second primary malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 0,
                                "unit": "non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's Medical monitor and investigator agree and document that it should not be exclusionary"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received systemic anticancer treatment or radiotherapy less than 2 weeks before the first dose of S095035. Participants who have not recovered from toxicity of previous anticancer therapy.",
            "criterions": [
                {
                    "exact_snippets": "received systemic anticancer treatment or radiotherapy less than 2 weeks before the first dose of S095035",
                    "criterion": "systemic anticancer treatment or radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have not recovered from toxicity of previous anticancer therapy",
                    "criterion": "toxicity of previous anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to take an orally administered drug, or medical disorder or prior surgical resection that may affect the absorption of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "Inability to take an orally administered drug",
                    "criterion": "ability to take orally administered drug",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "medical disorder ... that may affect the absorption of the study drug",
                    "criterion": "medical disorder affecting absorption of study drug",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior surgical resection that may affect the absorption of the study drug",
                    "criterion": "prior surgical resection affecting absorption of study drug",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks prior to the first IMP administration or participants who have not recovered from side effects of the surgery.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks prior to the first IMP administration",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participants who have not recovered from side effects of the surgery",
                    "criterion": "recovery from side effects of surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known prior severe hypersensitivity to any component of the study drug formulation.",
            "criterions": [
                {
                    "exact_snippets": "Known prior severe hypersensitivity to any component of the study drug formulation.",
                    "criterion": "severe hypersensitivity to any component of the study drug formulation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with a known clinically significant cardiovascular disease or condition.",
            "criterions": [
                {
                    "exact_snippets": "known clinically significant cardiovascular disease or condition",
                    "criterion": "cardiovascular disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to first IMP administration.",
            "criterions": [
                {
                    "exact_snippets": "Participants with thrombosis ... within 4 weeks prior to first IMP administration.",
                    "criterion": "thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of deep vein thrombosis ... within 4 weeks prior to first IMP administration.",
                    "criterion": "deep vein thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... pulmonary embolism, within 4 weeks prior to first IMP administration.",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}